Ventripoint Diagnostics Awards Options to Stakeholders
Toronto, Ontario -- February 11, 2024 -- NewsGenie -- Ventripoint Diagnostics Ltd. (TSXV:VPT, OTC:VPTDF) has announced the granting of 4,015,000 options to its directors, officers, employees, contractors, and consultants. These options, granted on January 20, 2025, have an exercise price of $0.10 and terms ranging from two to ten years, vesting immediately to over a three-year period.
Of the total options, 200,000 were granted to directors and an additional 325,000 to officers, some of whom also serve as directors. The company views these annual option grants as crucial for incentivizing stakeholders and driving value within the corporation.
Since the previous update on September 9, 2024, 153,200 options have been exercised at a weighted average price of approximately $0.13 per share, generating gross proceeds of $19,310 for Ventripoint. Currently, there are 11,762,750 option grants outstanding with exercise prices ranging from $0.10 to $0.50, and a weighted average price of $0.21. 8,652,750 of these options have vested.
Ventripoint has 3,231,641 options available for future grants under the Stock Option Plan, which was approved by shareholders on November 1, 2023.
Ventripoint is a leader in applying AI to echocardiography. Its VMS products utilize proprietary KBR technology, providing cardiac measurements comparable to MRI. This alternative gives cardiologists greater confidence in patient management.
Hugh MacNaught, President and CEO, can be contacted for further information at hmacnaught@ventripoint.com or (604) 671-4201.